These findings have potential implications for guiding the use of PI3K‒AKT inhibitors against endocrine-refractory tumors, i.e. PI3K‒AKT inhibitors may inadvertently activate pro-survival AMPK, autophagy, and FAO in tumor cells, leading to reduced therapeutic benefit of these inhibitors. This evidence concerns the gene AKT1 and neoplasm.